Biggest News Aggregation in the World
📰 Patrick Burnett News

Page 2 - Patrick Burnett News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Patrick Burnett. Real-time updates on events, politics, business and more.

FDA Approves Arcutis' ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older -December 15, 2023 at 05:12 pm EST

ZORYVE foam represents a highly effective, safe, well-tolerated, once-daily steroid-free foam for use on all affected areas of the body, including hair-bearing areas, with no limitations on duration...
United States Frank Watanabe Andrew Blauvelt Patrick Burnett Drug Administration Oregon Medical Research Center

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2023 Earnings Call Transcript

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2023 Earnings Call Transcript November 3, 2023 Arcutis Biotherapeutics, Inc. beats earnings expectations. Reported EPS is $-0.73, expectations were $-0.9. Operator: Good day, and welcome to the Arcutis Biotherapeutics Third Quarter 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like […]
Frank Watanabe Patricia Turney Bethany Dudek Patrick Burnett David Osborne John Smither
Source: yahoo.com

FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children ... | Region

WESTLAKE VILLAGE, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S.
United States Eric Mcintyre Amanda Sheldon Leahm Howard Patrick Burnett Exchange Commission

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science